Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening inBRCA1andBRCA2gene mutation carriers-Reference-Cited by-同舟云学术

Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening inBRCA1andBRCA2gene mutation carriers

Published:2012-11-26 Issue:6 Volume:119 Page:1266-1276
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Cott Chubiz Jessica E.,Lee Janie M.,Gilmore Michael E.,Kong Chung Y.,Lowry Kathryn P.,Halpern Elkan F.,McMahon Pamela M.,Ryan Paula D,Gazelle G. Scott

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference56 articles.

1. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies;Antoniou;Am J Hum Genet.,2003

2. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer;Lee;J Am Coll Radiol.,2010

3. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography;Saslow;CA Cancer J Clin.,2007

4. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer;Warner;Ann Intern Med.,2008

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost‐effectiveness of the McGill interactive pediatric oncogenetic guidelines in identifying Li–Fraumeni syndrome in female patients with osteosarcoma;Pediatric Blood & Cancer;2024-05-23

2. Economic evaluation of breast MRI in screening - a systematic review and basic approach to cost-effectiveness analyses;Frontiers in Oncology;2023-12-07

3. Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors;Journal of Clinical Oncology;2023-02-10

4. Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service;Scientific Reports;2022-11-03

5. Breast cancer incidence among women with a family history of breast cancer by relative's age at diagnosis;Cancer;2022-10-19